Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051247 | 0.92 | PTGES (0.49) | PPARGCETPFOLH1PTGESALOX5 | |
| SCHEMBL5054450 | 0.88 | CETP (0.43) | PPARGPPARACETPFOLH1SRR | |
| SCHEMBL5057950 | 0.87 | PPARG (0.50) | PPARGPPARASRR | |
| SCHEMBL1377537 | 0.85 | FOLH1 (0.52) | FOLH1SRR | |
| SCHEMBL5054717 | 0.84 | PPARG (0.52) | PPARGPPARA | |
| SCHEMBL5051251 | 0.83 | SRR (0.56) | PPARGPPARASRR | |
| SCHEMBL5053000 | 0.83 | ACE (0.52) | PPARGPPARA | |
| SCHEMBL5053058 | 0.83 | FOLH1 (0.47) | PPARGPPARAFOLH1SRR | |
| SCHEMBL5059834 | 0.82 | FOLH1 (0.46) | PPARGPPARAFOLH1 | |
| SCHEMBL5060232 | 0.81 | MAPT (0.45) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514160-A | — | — | 2002-05-14 | — | — | JP | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| US-6046180-A | NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | claimed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | claimed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | disclosed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | PPARG 3113/4885PPARA 2998/4885CETP 586/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | PPARG 751/4885PPARA 361/4885CETP 1402/4885 |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | PPARG 4038/4885PPARA 3385/4885CETP 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.